about
Mice deficient in transmembrane prostatic acid phosphatase display increased GABAergic transmission and neurological alterations.Analysis of oxysterols and vitamin D metabolites in mouse brain and cell line samples by ultra-high-performance liquid chromatography-atmospheric pressure photoionization-mass spectrometry.Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in miceQuantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice.Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumorsCatechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain.Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture?Association of prolyl oligopeptidase with conventional neurotransmitters in the brain.Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interactionInhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo.Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain.Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues.Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study.Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters.Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.Distribution of immunoreactive prolyl oligopeptidase in human and rat brain.Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.Constitutive Ret signaling leads to long-lasting expression of amphetamine-induced place conditioning via elevation of mesolimbic dopamine.Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.Sequential expression, activity and nuclear localization of prolyl oligopeptidase protein in the developing rat brain.Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington's diseaseNew tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseasesBehavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s diseaseProlyl oligopeptidase inhibition activates autophagy via protein phosphatase 2AAng II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-IndependentTetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors
P50
Q30438217-E74B60D8-1391-4F30-B6C8-715878BD6240Q33462853-A9E343E4-60B5-4D0A-AD50-D98FE77EF92BQ34060577-2F8D823B-D8A3-4778-A86B-3862DF8D3132Q34125744-A0D9B128-C862-4155-9633-370114912185Q35195523-47312255-55BB-4CC7-BACF-6079D37B8345Q36473292-1DDAE070-4A37-4A12-B39E-8827FCE7C5BCQ36773459-7A6DCBA8-DE01-47B7-A4ED-32AFCFBD2143Q37315924-575723A0-F3FC-42DF-96AA-B3618FEA5FE7Q37811520-014B8B99-F558-46C8-A080-0103A992999EQ37827532-B8E63689-1C09-4CC9-B4FD-F27A5A7A69BDQ38732589-A38BE2A8-EC5C-43D9-A330-D27556D46BA2Q38821744-ACFE0B91-7EC9-43C7-ADE5-E673A1CB8021Q38923732-7B3F4659-E593-45B0-87E7-0F573033E748Q38954711-A97EA50F-0D53-4685-A8DB-639FEE2D9501Q39002911-9078B158-EC07-4F61-AA14-DE9085F68200Q39414467-CD626749-06D9-4FA9-918C-7261CCADCDB3Q39504953-DEA8C525-C92A-4740-A0C4-4EA8353E8A9EQ40436578-9EE3C7F6-DC5D-434D-B827-F971E229F303Q42517568-7B14F3CD-C2B2-4B71-96C7-CE46A4B7828DQ46223574-5B779CB9-7D6D-42AA-B47C-53A7DC967F09Q46490051-F466E56D-94DE-4054-BA5E-169E2E239960Q46612471-B1CE08B5-E144-4708-9E08-48C08C798E7CQ46696288-41876F9F-790D-4C00-9EFD-F86C2D961E56Q46769240-05E2C29F-2242-4F6D-B432-C45D1B55D65BQ47549125-8F1A918B-E5AA-4F22-9EBC-6B662FCA1FC5Q48221259-E090B8BA-0622-42AE-BE0C-2CF4B5F5F08BQ48461582-8A62204F-C8DB-46E4-AB92-78D6860902FFQ50069089-AC43DB70-29D8-4533-A264-34168F30B092Q51267918-782AF46B-626B-47E0-B3A7-39610D8CAE46Q53282844-FAAC1766-ECDC-4558-89FA-FF4D5E3D5B41Q90359973-1B47584D-5A43-4D76-835B-766DAC17560CQ91123476-1DD92A1C-8C78-4B5B-A97D-44149BE80149Q91405170-B0ED411C-BFA4-4012-B92B-50B9A2C81CDDQ91410657-54454D48-BD73-4D97-88D6-B46FA23F68B1Q91577276-5CC4A6A1-D110-4ABF-A324-B7FFF99FC79BQ92133866-06596741-D35D-47D0-85CC-F75ECD7E86B1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Timo T Myöhänen
@nl
Timo T Myöhänen
@sl
Timo T. Myöhänen
@en
Timo T. Myöhänen
@es
type
label
Timo T Myöhänen
@nl
Timo T Myöhänen
@sl
Timo T. Myöhänen
@en
Timo T. Myöhänen
@es
altLabel
Timo T Myöhänen
@en
Timo Tapio Myöhänen
@en
prefLabel
Timo T Myöhänen
@nl
Timo T Myöhänen
@sl
Timo T. Myöhänen
@en
Timo T. Myöhänen
@es
P106
P1153
26646883000
P21
P31
P4012
P496
0000-0002-9277-6687